Publicacións en colaboración con investigadores/as de Hospital Universitari de Tarragona Joan XXIII (10)

2022

  1. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2020

  1. Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry)

    Arthritis Care and Research, Vol. 72, Núm. 7, pp. 1001-1010

2017

  1. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity

    Medicine (United States), Vol. 96, Núm. 8

2016

  1. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

    Lupus Science and Medicine, Vol. 3, Núm. 1

  2. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

  3. Systemic activity and mortality in primary Sjögren syndrome: Predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 2, pp. 348-355

2014

  1. Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: An Allergists' Consensus

    Clinical and Translational Allergy, Vol. 4, Núm. 1

  2. Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS disease activity index: Analysis of 921 spanish patients (GEAS-SS registry)

    Rheumatology (United Kingdom), Vol. 53, Núm. 2, pp. 321-331

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9